STOCK TITAN

Elanco (ELAN): T. Rowe Price discloses 6.4% stake, 09/30/2025

T. Rowe Price Investment Management, Inc. filed a Schedule 13G reporting beneficial ownership of 31,547,970 shares (6.4%) of Elanco Animal Health common stock as of 09/30/2025.

Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

T. Rowe Price Investment Management, Inc. filed a Schedule 13G reporting beneficial ownership of 31,547,970 shares (6.4%) of Elanco Animal Health common stock as of 09/30/2025.

The filer reports sole voting power over 31,482,581 shares and sole dispositive power over 31,547,970 shares, with no shared voting or dispositive power. It certifies the holdings were acquired and are held in the ordinary course and not for the purpose of changing or influencing control.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



T. Rowe Price Investment Management, Inc.
Signature:Ellen York
Name/Title:Vice President
Date:11/14/2025

Keep reading